- Approval Id
- 6b485501cfae3fee
- Drug Approval Emc Name
- Terlipressin Acetate 1 mg Powder and solvent for solution for injection
- Drug Name
- Terlipressin Acetate 1 mg Powder and solvent for solution for injection
- Company Address
- Drayton Hall, Church Road, West Drayton, UB7 7PS, UK
- Company Website
- http://www.ferring.co.uk
- Company Telephone
- +44 (0)844 931 0050
- Company Medical Info Email
- medical.uk@ferring.com
- Company Customer Care Direct Line
- 0800 111 4125
- Atc Code
- H01BA04
- Legal Category
- Prescription only medicine
- Authorisation Holder
- Ferring Pharmaceuticals Ltd
Drayton Hall
Church Road
West Drayton
UB7 7PS
UK
- Authorisation Number
- PL 03194/0018
- Authorisation Date
- October 1983 / 19th July 2001
- Instruction Authorisation Holder
- Ferring Pharmaceuticals Ltd
Drayton Hall
Church Road
West Drayton
UB7 7PS
UK
- Instruction Authorisation Number
- PL 03194/0018
- Instruction Authorisation Date
- October 1983 / 19th July 2001
- Instruction Composition
- Each vial contains 1mg Terlipressin Acetate
For excipients, see 6.1
- Instruction Dosage Form
- Powder and solvent for solution for injection -
Vial contains white, freeze-dried powder.
Ampoule contains solvent.
- Instruction Clinical Particulars
- 4.1 Therapeutic indications
Glypressin® is indicated in the treatment of bleeding oesophageal varices.4.2 Posology and method of administration
\*\*Posology\*\*
In acute variceal bleeding:
\*\*Adults:\*\*
Initially an i.v. injection of 2 mg Glypressin is given every 4 hours. The treatment should be maintained until bleeding has been controlled for 24 hours, but up to a maximum of 48 hours. After the initial dose, the dose can be adjusted to 1 mg i.v. every 4 hours in patients with body weight < 50 kg or if adverse effects occur.
\*\*Paediatric population:\*\*
There is no relevant use of Glypressin in paediatric population.
\*\*Method of administration\*\*
Intravenous injection use4.3 Contraindications
Contraindicated in pregnancy.
Hypersensitivity to terlipressin acetate or any of the excipients listed in section 6.1.4.4 Special warnings and precautions for use
\*\*Monitoring during treatment\*\*
During treatment regular monitoring of blood pressure, ECG or heart rate, oxygen saturation, serum levels of sodium and potassium, as well as fluid balance are required.
Particular care is required in the management of patients with cardiovascular or pulmonary disease since terlipressin may induce ischaemia and pulmonary vascular congestion.
Caution should also be exercised in treating patients with hypertension.
\*\*Injection site reaction\*\*
To avoid local necrosis at the injection site, the injection must be given i.v.
\*\*Septic shock\*\*
In patients with septic shock with a low cardiac output Glypressin should not be used.
\*\*Skin necrosis\*\*
During post-marketing experience with terlipressin several cases of cutaneous ischaemia and necrosis unrelated to the injection site have been reported (see section 4.8). Patients with diabetes mellitus and obesity seem to have a greater tendency to this reaction. Therefore, caution should be exercised when administering terlipressin in these patients.
\*\*Torsade de pointes\*\*
During clinical trials and post-marketing experience, several cases of QT interval prolongation and ventricular arrhythmias including “Torsade de pointes” have been reported (see section 4.8). In most cases, patients had predisposing factors such as basal prolongation of the QT interval, electrolyte abnormalities (hypokalemia, hypomagnesemia) or medications with concomitant effect on QT prolongation. Therefore, extreme caution should be exercised in the use of terlipressin in patients with a history of QT interval prolongation, electrolyte abnormalities, or concomitant medications that can prolong the QT interval (see section 4.5).
Children and the elderly: Particular caution should be exercised in the treatment of children and elderly patients, as experience is limited in these groups.
There is no data available regarding dosage recommendation in these special patient categories.4.5 Interaction with other medicinal products and other forms of interaction
The hypotensive effect of non-selective beta-blockers on the portal vein is increased with terlipressin. Concomitant treatment with medicinal products with a known bradycardic effect (e.g. propofol, sufentanil) may lower the heart rate and cardiac output. These effects are due to reflexogenic inhibition of cardiac activity via the vagus nerve due to the elevated blood pressure.
Terlipressin can trigger “torsade de pointes” (see sections 4.4 and 4.8). Therefore, extreme caution should be exercised in the use of terlipressin in patients with concomitant medications that can prolong the QT interval, such as class IA and III antiarrhythmics, erythromycin, certain antihistamines and tricyclic antidepressants or medications that may cause hypokalaemia or hypomagnesemia (e.g. some diuretics).4.6 Fertility, pregnancy and lactation
\*\*Pregnancy\*\*
Treatment with Glypressin during pregnancy is contraindicated (ref. 4.3 and 5.3).
Glypressin has been shown to cause uterine contractions and increased intrauterine pressure in early pregnancy and may decrease uterine blood flow. Glypressin may have harmful effects on pregnancy and foetus.
Spontaneous abortion and malformation have been shown in rabbits after treatment with Glypressin.
\*\*Breast-feeding\*\*
It is not known whether terlipressin is excreted in human breast milk. The excretion of terlipressin in milk has not been studied in animals. A risk to the suckling child cannot be excluded. A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with terlipressin should be made taking into account the benefit of breast-feeding to the child and the benefit of terlipressin therapy to the woman.4.7 Effects on ability to drive and use machines
No studies on the effects on the ability to drive and use machines have been performed.4.8 Undesirable effects
\*\*Summary of safety profile\*\*
The most frequently reported undesirable effects in clinical trials are abdominal pain, nausea, diarrhoea, pallor, vomiting, and bradycardia.
\*\*\*Table: Frequency of undesirable effects\*\*\*
| | | | | |
| --- | --- | --- | --- | --- |
| \*\*SYSTEM ORGAN CLASS\*\* | \*\*Frequency\*\* | | | |
| \*\*VERY COMMON\*\* >1/10 | \*\*COMMON\*\* ≥1/100 to <1/10 | \*\*UNCOMMON\*\* ≥ 1/1,000 to < 1/100 | \*\*FREQUENCY NOT KNOWN\\*\*\* |
| \*\*Metabolism and nutrition disorders\*\* | | Hyponatraemia | | |
| \*\*Nervous system Disorders\*\* | | Headache | | |
| \*\*Cardiac disorders\*\* | | Chest pain Bradycardia Tachycardia | Atrial fibrillation Myocardial infarction Torsade de pointes Cardiac failure Ventrical extrasystoles\\*\\* | |
| \*\*Vascular disorders\*\* | | Vasoconstriction Peripheral ischaemia Pallor Hypertension Cyanosis | Hot flush | |
| \*\*Respiratory thoracic and mediastinal disorders\*\* | | Pulmonary oedema Dyspnoea | Respiratory failure Respiratory distress | |
| \*\*Gastrointestinal disorders\*\* | Abdominal Pain | Diarrhoea Nausea Vomiting | Intestinal ischaemia | |
| \*\*Skin and subcutaneous tissue disorders\*\* | | | Skin necrosis (unrelated to the site of administration)\\*\\*, \\*\\*\\* | |
| \*\*Pregnancy, puerperium and perinatal conditions\*\* | | | | Uterine hypertonus |
| \*\*Reproductive system and breast disorders\*\* | | | | Uterine ischemia |
| \*\*General disorders and administration site disorders\*\* | | | Injection site necrosis | |
\\* Frequencies of these adverse events cannot be estimated from the available data
\\*\\* Adverse reactions identified from post-marketing sources are presented by frequency category based on a theoretically calculated frequency if not observed in clinical trials
\\*\\*\\* See section 4.4 for further information
\*\*Reporting of suspected adverse reactions\*\*
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme, website: www.mhra.gov.uk/yellowcard.4.9 Overdose
The recommended dose in the specific patient population should not be exceeded as the risk of severe circulatory adverse effects is dose-dependent.
- Instruction Pharmacology
- 5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Posterior pituitary lobe hormones (vasopressin and analogues) (H 01 BA 04)
Terlipressin (Triglycyl-Lysine-Vasopressin) is a synthetic analogue of the natural posterior pituitary hormone vasopressin.
Terlipressin is a pro-drug with partial, intrinsic activity by itself. Terlipressin is transformed into the fully active metabolite lysine-vasopressin (LVP) by enzymatic cleavage. Doses of 1 and 2 mg terlipressin acetate effectively reduce the portal venous pressure and produce marked vasoconstriction. The lowering of portal pressure and azygos blood flow is dependent on dose. The effect of the low dose is reduced after 3 hours, while haemodynamic data show that 2 mg is more effective than 1 mg with a sustained effect throughout the treatment period of 4 to 6 hours.5.2 Pharmacokinetic properties
The pharmacokinetics follows a two-compartment model with a rapid distribution phase.
\*\*Absorption\*\*
Terlipressin is administered by the intravenous route resulting in instant systemic exposure.
\*\*Distribution\*\*
In patients with liver cirrhosis with or without hepatorenal syndrome the mean distribution volume was reported in the range 0.2 to 0.5 l/kg in two clinical trials in Japanese and Caucasian subjects, respectively.
\*\*Biotransformation\*\*
The concentration of the active metabolite, lysine-vasopressin, starts to increase approximately 30 minutes after bolus administration of terlipressin and peak levels are reached between 60 and 120 minutes after administration of terlipressin.
\*\*Elimination\*\*
The terminal elimination half-life of terlipressin is approximately 40 minutes in patients with liver cirrhosis with and without hepatorenal syndrome and the mean clearance was reported in the range 5 to 9 ml/kg/min in two clinical trials in Japanese and Caucasian subjects, respectively.
\*\*Linearity\*\*
Terlipressin demonstrated a dose-dependent and approximate proportional increase in total exposure (AUC) after single i.v. injections to healthy subjects (n=2-14 subjects per dose group) in a dose range between 5 and 30 µg/kg.5.3 Preclinical safety data
There are no pre-clinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.
- Instruction Pharmaceutical Particulars
- 6.1 List of excipients
Vial:
Mannitol
Hydrochloric Acid 1M
Solvent Ampoule:
Sodium Chloride
Hydrochloric Acid 1M
Water for Injection6.2 Incompatibilities
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.6.3 Shelf life
36 months6.4 Special precautions for storage
Do not store above 25°C. Keep container in the outer carton.6.5 Nature and contents of container
| | |
| --- | --- |
| Powder: | Type I glass vial |
| Solvent: | Type I glass ampoule |
Pack size:
Cartons containing 5 packs, each with one vial of powder and one ampoule of 5ml solvent.6.6 Special precautions for disposal and other handling
Prior to injection, the powder should be reconstituted with the solvent provided. Use immediately after reconstitution.
Any unused product or waste material should be disposed of in accordance with local requirements.
- Instruction Content
- ## Composition
Each vial contains 1mg Terlipressin Acetate
For excipients, see 6.1
## Pharmaceutical Form
Powder and solvent for solution for injection -
Vial contains white, freeze-dried powder.
Ampoule contains solvent.
## Clinical Particulars
4.1 Therapeutic indications
Glypressin® is indicated in the treatment of bleeding oesophageal varices.4.2 Posology and method of administration
\*\*Posology\*\*
In acute variceal bleeding:
\*\*Adults:\*\*
Initially an i.v. injection of 2 mg Glypressin is given every 4 hours. The treatment should be maintained until bleeding has been controlled for 24 hours, but up to a maximum of 48 hours. After the initial dose, the dose can be adjusted to 1 mg i.v. every 4 hours in patients with body weight < 50 kg or if adverse effects occur.
\*\*Paediatric population:\*\*
There is no relevant use of Glypressin in paediatric population.
\*\*Method of administration\*\*
Intravenous injection use4.3 Contraindications
Contraindicated in pregnancy.
Hypersensitivity to terlipressin acetate or any of the excipients listed in section 6.1.4.4 Special warnings and precautions for use
\*\*Monitoring during treatment\*\*
During treatment regular monitoring of blood pressure, ECG or heart rate, oxygen saturation, serum levels of sodium and potassium, as well as fluid balance are required.
Particular care is required in the management of patients with cardiovascular or pulmonary disease since terlipressin may induce ischaemia and pulmonary vascular congestion.
Caution should also be exercised in treating patients with hypertension.
\*\*Injection site reaction\*\*
To avoid local necrosis at the injection site, the injection must be given i.v.
\*\*Septic shock\*\*
In patients with septic shock with a low cardiac output Glypressin should not be used.
\*\*Skin necrosis\*\*
During post-marketing experience with terlipressin several cases of cutaneous ischaemia and necrosis unrelated to the injection site have been reported (see section 4.8). Patients with diabetes mellitus and obesity seem to have a greater tendency to this reaction. Therefore, caution should be exercised when administering terlipressin in these patients.
\*\*Torsade de pointes\*\*
During clinical trials and post-marketing experience, several cases of QT interval prolongation and ventricular arrhythmias including “Torsade de pointes” have been reported (see section 4.8). In most cases, patients had predisposing factors such as basal prolongation of the QT interval, electrolyte abnormalities (hypokalemia, hypomagnesemia) or medications with concomitant effect on QT prolongation. Therefore, extreme caution should be exercised in the use of terlipressin in patients with a history of QT interval prolongation, electrolyte abnormalities, or concomitant medications that can prolong the QT interval (see section 4.5).
Children and the elderly: Particular caution should be exercised in the treatment of children and elderly patients, as experience is limited in these groups.
There is no data available regarding dosage recommendation in these special patient categories.4.5 Interaction with other medicinal products and other forms of interaction
The hypotensive effect of non-selective beta-blockers on the portal vein is increased with terlipressin. Concomitant treatment with medicinal products with a known bradycardic effect (e.g. propofol, sufentanil) may lower the heart rate and cardiac output. These effects are due to reflexogenic inhibition of cardiac activity via the vagus nerve due to the elevated blood pressure.
Terlipressin can trigger “torsade de pointes” (see sections 4.4 and 4.8). Therefore, extreme caution should be exercised in the use of terlipressin in patients with concomitant medications that can prolong the QT interval, such as class IA and III antiarrhythmics, erythromycin, certain antihistamines and tricyclic antidepressants or medications that may cause hypokalaemia or hypomagnesemia (e.g. some diuretics).4.6 Fertility, pregnancy and lactation
\*\*Pregnancy\*\*
Treatment with Glypressin during pregnancy is contraindicated (ref. 4.3 and 5.3).
Glypressin has been shown to cause uterine contractions and increased intrauterine pressure in early pregnancy and may decrease uterine blood flow. Glypressin may have harmful effects on pregnancy and foetus.
Spontaneous abortion and malformation have been shown in rabbits after treatment with Glypressin.
\*\*Breast-feeding\*\*
It is not known whether terlipressin is excreted in human breast milk. The excretion of terlipressin in milk has not been studied in animals. A risk to the suckling child cannot be excluded. A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with terlipressin should be made taking into account the benefit of breast-feeding to the child and the benefit of terlipressin therapy to the woman.4.7 Effects on ability to drive and use machines
No studies on the effects on the ability to drive and use machines have been performed.4.8 Undesirable effects
\*\*Summary of safety profile\*\*
The most frequently reported undesirable effects in clinical trials are abdominal pain, nausea, diarrhoea, pallor, vomiting, and bradycardia.
\*\*\*Table: Frequency of undesirable effects\*\*\*
| | | | | |
| --- | --- | --- | --- | --- |
| \*\*SYSTEM ORGAN CLASS\*\* | \*\*Frequency\*\* | | | |
| \*\*VERY COMMON\*\* >1/10 | \*\*COMMON\*\* ≥1/100 to <1/10 | \*\*UNCOMMON\*\* ≥ 1/1,000 to < 1/100 | \*\*FREQUENCY NOT KNOWN\\*\*\* |
| \*\*Metabolism and nutrition disorders\*\* | | Hyponatraemia | | |
| \*\*Nervous system Disorders\*\* | | Headache | | |
| \*\*Cardiac disorders\*\* | | Chest pain Bradycardia Tachycardia | Atrial fibrillation Myocardial infarction Torsade de pointes Cardiac failure Ventrical extrasystoles\\*\\* | |
| \*\*Vascular disorders\*\* | | Vasoconstriction Peripheral ischaemia Pallor Hypertension Cyanosis | Hot flush | |
| \*\*Respiratory thoracic and mediastinal disorders\*\* | | Pulmonary oedema Dyspnoea | Respiratory failure Respiratory distress | |
| \*\*Gastrointestinal disorders\*\* | Abdominal Pain | Diarrhoea Nausea Vomiting | Intestinal ischaemia | |
| \*\*Skin and subcutaneous tissue disorders\*\* | | | Skin necrosis (unrelated to the site of administration)\\*\\*, \\*\\*\\* | |
| \*\*Pregnancy, puerperium and perinatal conditions\*\* | | | | Uterine hypertonus |
| \*\*Reproductive system and breast disorders\*\* | | | | Uterine ischemia |
| \*\*General disorders and administration site disorders\*\* | | | Injection site necrosis | |
\\* Frequencies of these adverse events cannot be estimated from the available data
\\*\\* Adverse reactions identified from post-marketing sources are presented by frequency category based on a theoretically calculated frequency if not observed in clinical trials
\\*\\*\\* See section 4.4 for further information
\*\*Reporting of suspected adverse reactions\*\*
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme, website: www.mhra.gov.uk/yellowcard.4.9 Overdose
The recommended dose in the specific patient population should not be exceeded as the risk of severe circulatory adverse effects is dose-dependent.
## Pharmacological Properties
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Posterior pituitary lobe hormones (vasopressin and analogues) (H 01 BA 04)
Terlipressin (Triglycyl-Lysine-Vasopressin) is a synthetic analogue of the natural posterior pituitary hormone vasopressin.
Terlipressin is a pro-drug with partial, intrinsic activity by itself. Terlipressin is transformed into the fully active metabolite lysine-vasopressin (LVP) by enzymatic cleavage. Doses of 1 and 2 mg terlipressin acetate effectively reduce the portal venous pressure and produce marked vasoconstriction. The lowering of portal pressure and azygos blood flow is dependent on dose. The effect of the low dose is reduced after 3 hours, while haemodynamic data show that 2 mg is more effective than 1 mg with a sustained effect throughout the treatment period of 4 to 6 hours.5.2 Pharmacokinetic properties
The pharmacokinetics follows a two-compartment model with a rapid distribution phase.
\*\*Absorption\*\*
Terlipressin is administered by the intravenous route resulting in instant systemic exposure.
\*\*Distribution\*\*
In patients with liver cirrhosis with or without hepatorenal syndrome the mean distribution volume was reported in the range 0.2 to 0.5 l/kg in two clinical trials in Japanese and Caucasian subjects, respectively.
\*\*Biotransformation\*\*
The concentration of the active metabolite, lysine-vasopressin, starts to increase approximately 30 minutes after bolus administration of terlipressin and peak levels are reached between 60 and 120 minutes after administration of terlipressin.
\*\*Elimination\*\*
The terminal elimination half-life of terlipressin is approximately 40 minutes in patients with liver cirrhosis with and without hepatorenal syndrome and the mean clearance was reported in the range 5 to 9 ml/kg/min in two clinical trials in Japanese and Caucasian subjects, respectively.
\*\*Linearity\*\*
Terlipressin demonstrated a dose-dependent and approximate proportional increase in total exposure (AUC) after single i.v. injections to healthy subjects (n=2-14 subjects per dose group) in a dose range between 5 and 30 µg/kg.5.3 Preclinical safety data
There are no pre-clinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.
## Pharmaceutical Particulars
6.1 List of excipients
Vial:
Mannitol
Hydrochloric Acid 1M
Solvent Ampoule:
Sodium Chloride
Hydrochloric Acid 1M
Water for Injection6.2 Incompatibilities
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.6.3 Shelf life
36 months6.4 Special precautions for storage
Do not store above 25°C. Keep container in the outer carton.6.5 Nature and contents of container
| | |
| --- | --- |
| Powder: | Type I glass vial |
| Solvent: | Type I glass ampoule |
Pack size:
Cartons containing 5 packs, each with one vial of powder and one ampoule of 5ml solvent.6.6 Special precautions for disposal and other handling
Prior to injection, the powder should be reconstituted with the solvent provided. Use immediately after reconstitution.
Any unused product or waste material should be disposed of in accordance with local requirements.
- Company Detail Path
- /organization/08fbae02f5bf33aa/ferring-pharmaceuticals-inc
